Premium
Thyrocare Technologies Ltd had made a spectacular debut on the stock exchanges two years ago. But its share prices have fallen from the highs, prompting the diagnostics company to buy the stock back from the market to show its confidence. Its larger peer Dr Lal PathLabs Ltd, which became the ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
